News
Important Only
Tvardi Therapeutics Tti-101 Shows 9.4% Fibrosis Score Decrease Versus 2.4% Placebo
Jan 8 (Reuters) - Tvardi Therapeutics Inc TVRD.O:TVARDI THERAPEUTICS INC - TTI-101 SHOWS 9.4% FIBROSIS SCORE DECREASE VERSUS 2.4% PLACEBOTVARDI THERAPEUTICS INC - TOPLINE HEALTHY VOLUNTEER DATA FROM PHASE 1 STUDY OF NEXT-GENERATION STAT3 INHIBITOR, TTI-109, ON TRACK FOR H1 2026Reuters
Thu, Jan 8
Annexon Submits Tanruprubart Marketing Authorization Application To The European Medicines Agency For Guillain-Barré Syndrome
Jan 8 (Reuters) - Annexon Inc ANNX.O:ANNEXON SUBMITS TANRUPRUBART MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR GUILLAIN-BARRÉ SYNDROMEANNEXON INC: BLA SUBMISSION WITH U.S./EUROPEAN DATA FROM FORWARD TRIAL PLANNED IN 2026Reuters
Thu, Jan 8
Cormedix Therapeutics Announces Preliminary Fourth Quarter And Full Year 2025 Results
Jan 8 (Reuters) - CorMedix Inc CRMD.O:CORMEDIX THERAPEUTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND PROVIDES BUSINESS UPDATESQ4 2025 UNAUDITED NET REVENUE ABOUT $127 MILLIONEXPECTS Q4 ADJUSTED EBITDA BETWEEN $77 MILLION AND $81 MILLIONINTRODUCES FY 2026 REVENUE GUIDANCE $...Reuters
Thu, Jan 8
Cytomx Therapeutics Announces Business Update And Company Milestones For 2026
Jan 8 (Reuters) - CytomX Therapeutics Inc CTMX.O:CYTOMX THERAPEUTICS ANNOUNCES BUSINESS UPDATE AND COMPANY MILESTONES FOR 2026CYTOMX THERAPEUTICS INC - CX-2051 PHASE 1 DATA ON TRACK FOR Q1 2026CYTOMX THERAPEUTICS: INITIAL CX-801 PHASE 1 COMBINATION DATA WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA EXPE...Reuters
Thu, Jan 8
Halozyme Announces Global Collaboration And License Agreement With Takeda
Jan 8 (Reuters) - Halozyme Therapeutics Inc HALO.O:HALOZYME ANNOUNCES GLOBAL COLLABORATION AND LICENSE AGREEMENT WITH TAKEDA TO DEVELOP AND COMMERCIALIZE VEDOLIZUMAB WITH ENHANZE®HALOZYME THERAPEUTICS INC - TAKEDA GAINS EXCLUSIVE ACCESS TO ENHANZE TECHNOLOGYHALOZYME THERAPEUTICS INC - TAKEDA TO MAKE...Reuters
Thu, Jan 8
Haveli to buy majority stake in contract software firm Sirion
By Isla BinnieJan 8 (Reuters) - U.S. private equity firm Haveli Investments has agreed to make a majority investment in Sirion, which provides software that uses artificial intelligence to draft, store and manage business contracts, the companies said on Thursday.WHAT HAS BEEN AGREED?Haveli will buy...Reuters
Thu, Jan 8
Frontier Airlines parent company appoints new CEO
Jan 8 (Reuters) - Frontier Group ULCC.O, parent company of Frontier Airlines, said on Thursday the board appointed James G. Dempsey as its Chief Executive Officer.Last month, the company announced the departure of longtime CEO Barry Biffle and named insider Dempsey as interim chief.Frontier also sai...Reuters
Thu, Jan 8
